MOTS-c: research overview

The short version

MOTS-c is a small peptide, sixteen amino acids long, and unusual in where it comes from. Almost every protein in a human cell is built from instructions in the cell nucleus. The instructions for MOTS-c sit instead inside the mitochondrial genome — the separate, much smaller ring of DNA carried by the mitochondria themselves. The sequence is highly conserved across mammals, which usually means evolution has kept it for a reason.

Cells make it on their own, and exercise raises how much of it circulates ^[4]. Given to mice, it improved physical performance at young, middle and old age ^[4], prevented muscle wasting and increased glucose uptake in muscle ^[1]. In people, nobody has run a trial of administering it. The human evidence is of a different kind: how much of the peptide is already in someone's blood tracks with how they fare ^[2].

It is not an approved medicine anywhere, it is sold for laboratory use only, and it is treated as a prohibited substance in elite sport.

What it is

MOTS-c — Mitochondrial Open Reading Frame of the 12S rRNA type-c — is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR. It is encoded by a short open reading frame lying inside the mitochondrial 12S ribosomal RNA gene, MT-RNR1, and it belongs to the class known as mitochondrial-derived peptides, or MDPs: molecules written into mitochondrial DNA that act as signals to the rest of the cell.

It appears in the literature and in supplier catalogues under several names — MOTS-c peptide, mitochondrial-derived peptide MOTS-c, MT-RNR1-encoded peptide, mitochondrial open reading frame of 12S rRNA-c. They refer to the same molecule.

Its formal classification here is a mitochondrial-derived signalling peptide for research use. That phrasing is not a hedge: there is no approved formulation, no approved indication and no human dosing standard for it to depart from.

How it works

The best-characterised action is metabolic. MOTS-c inhibits the folate cycle and, through it, de novo purine biosynthesis. That inhibition causes the intermediate AICAR to accumulate, and AICAR activates AMP-activated protein kinase, or AMPK — the enzyme a cell uses to register that energy is short and to switch toward burning fuel rather than storing it. The downstream effect is improved glucose handling and insulin sensitivity, most clearly in skeletal muscle.

The second action is stranger and is why the peptide is interesting to ageing biology at all. Under metabolic stress, MOTS-c leaves the mitochondrion and moves into the nucleus, where it regulates nuclear gene expression in an AMPK-dependent fashion, including antioxidant-response-element genes reached through the stress transcription factor NRF2 ^[5]. This was the first demonstration of retrograde signalling — mitochondrion instructing nucleus — by a mitochondrial-encoded peptide.

A 2024 study added a direct molecular target: MOTS-c binds and activates casein kinase 2 (CK2) in cell-free systems, and modulates CK2 in a tissue-specific way — activation in muscle, suppression in fat — which the authors link to its effects on muscle glucose uptake and on the prevention of atrophy ^[1].

Its named targets, then, are AMPK as the downstream effector, the folate-cycle enzymes and purine synthesis upstream of it, NRF2 and the antioxidant-response genes it governs, CK2 as a direct binding partner, and skeletal muscle as the primary target organ.

What the research shows

Direct target identification, 2024. In mice — young, aged, high-fat-diet and immobilised — together with cell-free assays, MOTS-c was shown to bind and activate CK2 directly, and tissue-specific CK2 modulation was proposed as the mechanism behind prevention of skeletal muscle atrophy and enhanced muscle glucose uptake ^[1].

Exercise inducibility and physical decline, 2021. Exercise induced endogenous MOTS-c expression in skeletal muscle and in circulation, and exogenous MOTS-c significantly enhanced physical performance in mice at 2, 12 and 22 months of age. In the aged group, 22 to 23.5 months, treadmill running capacity increased with a reported P value of 0.000002, alongside improvements in grip strength and gait ^[4]. This is the study that produced the "exercise-mimetic" framing.

Retrograde signalling, 2018. In human and mouse cells — HEK293 and fibroblasts — metabolic stress drove MOTS-c into the nucleus, where it regulated antioxidant and metabolic gene programmes in an AMPK-dependent manner through interaction with stress-responsive transcription factors including NRF2 ^[5].

Human association data, 2024. In a prospective multicentre cohort of 94 chronic haemodialysis patients followed for a median of 26.5 months, circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox hazard ratio 1.004, p=0.05), and adding it to the risk model improved discrimination, with the ROC area under the curve moving from 0.727 to 0.743 ^[2]. This is among the strongest human clinical-association data available for the peptide, and it is worth being precise about what it is: an observation about the body's own MOTS-c in a specific patient population, not a test of giving anyone any.

Orientation reference, 2023. A comprehensive review consolidates the biology — the MT-RNR1 origin, the AMPK and folate-cycle mechanism, nuclear translocation, exercise inducibility, and the peptide's roles across metabolic, stress-adaptive and ageing pathways ^[3].

Reported effects, cautions & safety

The corpus behind this desk carries no curated set of community reports for MOTS-c and no compound-specific safety-caution entries, so none are summarised here. That absence is not a safety finding. It reflects the state of the record: no human interventional trial has been run, so there is no adverse-event profile to report and no controlled safety characterisation to cite.

What the record does carry is a set of clearly stated limits.

No human efficacy trials. Every claim that exogenous MOTS-c improves metabolism, performance or ageing comes from cell or animal work, predominantly mice and rats. The human data are observational biomarker associations, not interventional outcomes.

No validated human pharmacokinetics. There is no published, measured human half-life, bioavailability or dose-response. The dose ranges used in rodent experiments have no established human equivalent and cannot be extrapolated into one.

Research-chemical status. MOTS-c is not approved by the FDA for any use and is sold only for laboratory research. Purity, identity and sterility vary by supplier and are not regulated as they are for pharmaceuticals.

Anti-doping prohibition. Anti-doping authorities treat MOTS-c as a prohibited peptide in elite sport under hormone-and-metabolic-modulator categories, and athletes face sanctions.

Small samples and thin replication. Several of the human biomarker studies are small or preliminary, and some mechanistic effects still await independent confirmation.

Effects may not be uniform across people. A pro-diabetogenic MOTS-c mitochondrial DNA variant and ancestry-dependent exercise responses have both been described, which argues against assuming one response curve for everyone.

Consumer claims run ahead of the evidence. Public interest in fat loss, longevity and performance, and the search demand that follows it, greatly exceed the strength of the clinical record. Closing that gap with context rather than with enthusiasm is the reason this page exists.

Where it fits in the healthspan question

MOTS-c sits cleanly on the healthspan side of the distinction this desk is organised around, and it sits there by default rather than by achievement: nobody has published a survival curve for it. Its ageing evidence is functional — how far an old mouse runs, how hard it grips, how it walks, whether an immobilised muscle wastes ^[4][1]. Those are the measurements healthspan is made of, and they are also the measurements a person would notice.

The exercise-mimetic framing deserves one caution. That exercise raises endogenous MOTS-c, and that administered MOTS-c improves performance in mice, are two findings from the same paper ^[4]. Together they make a hypothesis — that some of exercise's benefit is carried by this peptide, and that supplying it might stand in for part of the work. Neither finding demonstrates the substitution, and no human study has tested it.

The human association result cuts the same way. Circulating MOTS-c carried prognostic information in dialysis patients ^[2], which is consistent with the peptide indexing something real about mitochondrial and metabolic health. It is equally consistent with the peptide being a readout of that health rather than a lever on it. The study design cannot distinguish the two, and neither can this page.